fda compounding semaglutide crackdown news november 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Novo Nordisk expands legal action

Bachem Holding, the Swiss specialty peptide CDMO, disclosed in its 2024 annual report that GLP-1 peptides including semaglutide represent its single largest and fastest-growing revenue segment, accounting for approximately 31% of group sales

In vitro toxicity evaluation of graphene oxide and reduced graphene oxide on Caco-2 cells

Serious Risks of GLP-1 Medications While rare, some side effects require immediate medical attention: 1

Este medicamento no deve ser utilizado por menores de 18 anos sem orientao mdica

Thank you! Precautions Warning: Not to be used with peripheral vascular disease, high blood pressure, liver disease due to alcoholism (cirrhosis), diabetes, kidney disease, or a history of seizures